Neary James
Known title: DirectorCIK: 0001323057
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
WEX Shares Stretch as Company Expands AI Claims Tool. WEX is expanding its AI claims tool, a move that has pushed the stock higher but also stretched its valuation. The shares are trading near the $148.41 support level, which has been tested 10 times. Investors are watching how the new AI features will impact the company’s earnings and pricing.
Transaction History
| SHC | ▲ Buy | Grant | 14,970 | $0 | 5/22/2026 | View on chart |
| SHC | ▲ Buy | Grant | 19,132 | $0 | 5/22/2025 | View on chart |
| WEX | ▲ Buy | Option Exercise | 960 | $0 | 5/9/2025 | View on chart |
| SHC | ▲ Buy | Grant | 20,089 | $0 | 5/24/2024 | View on chart |
| WEX | ▲ Buy | Option Exercise | 1,147 | $0 | 5/11/2024 | View on chart |
| SHC | ▲ Buy | Grant | 15,712 | $0 | 5/26/2023 | View on chart |
| WEX | ▲ Buy | Option Exercise | 1,030 | $0 | 5/12/2023 | View on chart |
| WEX | ▲ Buy | Option Exercise | 760 | $0 | 6/4/2022 | View on chart |
| SHC | ▲ Buy | Grant | 10,643 | $0 | 5/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17
JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.